PMID- 31090627
OWN - NLM
STAT- MEDLINE
DCOM- 20200327
LR  - 20200511
IS  - 1531-7013 (Electronic)
IS  - 1087-2418 (Print)
IS  - 1087-2418 (Linking)
VI  - 24
IP  - 3
DP  - 2019 Jun
TI  - Impact of pretransplant antibodies on outcomes after heart transplantation.
PG  - 220-226
LID - 10.1097/MOT.0000000000000629 [doi]
AB  - PURPOSE OF REVIEW: Since the discovery of human leukocyte antigen (HLA) in the 
      1950s, there has been great interest in the role of antibodies in posttransplant 
      rejection. The development of the lymphocyte toxicity test by Terasaki et al. in 
      the 1960s was the first step toward understanding the role of antibodies in 
      posttransplant rejection. RECENT FINDINGS: Subsequently, various organs have been 
      transplanted and improving posttransplant outcomes have become a focus of 
      research. In particular, methods to measure antibodies that affect posttransplant 
      outcomes, including anti-HLA antibodies, and methods to desensitize patients from 
      specific antibodies have been explored. One recent method for measuring 
      antibodies is called the solid-phase assay, which uses purified HLA fixed to 
      microbeads. This assay does not use donor lymphocytes and allows clinicians to 
      test the reactivity of patient serum against a panel of antibodies. It has also 
      enabled the identification of specific anti-HLA antibodies using a single HLA. 
      SUMMARY: In addition to advances in methods to measure and analyze anti-HLA 
      antibodies, the clinical impact of non-HLA antibodies has also received much 
      attention recently.
FAU - Nunoda, Shinichi
AU  - Nunoda S
AD  - Department of Therapeutic Strategy for Severe Heart Failure, Graduate School of 
      Medicine, Tokyo Women's Medical University, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Organ Transplant
JT  - Current opinion in organ transplantation
JID - 9717388
RN  - 0 (Antibodies)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Antibodies/*immunology
MH  - Graft Rejection/*immunology
MH  - HLA Antigens/immunology
MH  - *Heart Transplantation
MH  - Histocompatibility Antigens Class II/immunology
MH  - Histocompatibility Testing
MH  - Humans
MH  - Transplantation Immunology
PMC - PMC6531009
EDAT- 2019/05/16 06:00
MHDA- 2020/03/28 06:00
PMCR- 2019/05/22
CRDT- 2019/05/16 06:00
PHST- 2019/05/16 06:00 [entrez]
PHST- 2019/05/16 06:00 [pubmed]
PHST- 2020/03/28 06:00 [medline]
PHST- 2019/05/22 00:00 [pmc-release]
AID - 00075200-201906000-00003 [pii]
AID - MOT240306 [pii]
AID - 10.1097/MOT.0000000000000629 [doi]
PST - ppublish
SO  - Curr Opin Organ Transplant. 2019 Jun;24(3):220-226. doi: 
      10.1097/MOT.0000000000000629.